A PHASE III RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ADMINISRATION OF BI10773 25 MG/LINAGLIPTIN 5MG AND BI10773 10 MG/LINAGLIPTIN 5MG FIXED DOSE COMBINATION TABLETS COMPARED WITH THE
Principal Investigator(s)
Cersosimo,Eugenio
Funded by
BOEHRINGER INGELHEIM PHARMACEUTICALS
Research Start Date
Status
Inactive